Dialysis

American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation

Friday, September 18, 2020 - 9:30pm

The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability or wrongdoing attributed to them.

Key Points: 
  • The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability or wrongdoing attributed to them.
  • Current shareholders may access a notice describing the proposed settlement and the agreement setting forth its terms on the Company's Investor Relations webpage.
  • American Renal Associates (ARA) is a leading provider of outpatient dialysis services in the United States.
  • For more information about American Renal Associates, visit www.americanrenal.com .

National Kidney Foundation Statement on the ESRD Treatment Choices Model (ETC) and Policies to Improve Kidney Patient Choice

Friday, September 18, 2020 - 6:44pm

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- "The National Kidney Foundation (NKF) is pleased to support the three linchpin policies of the Advancing American Kidney Health (AAKH) initiative finalized this morning.

Key Points: 
  • NEW YORK, Sept. 18, 2020 /PRNewswire/ -- "The National Kidney Foundation (NKF) is pleased to support the three linchpin policies of the Advancing American Kidney Health (AAKH) initiative finalized this morning.
  • "The End Stage Renal Disease (ESRD) Treatment Choices Model finalized by the Center for Medicare and Medicaid Innovation (CMMI) today will dramatically increase the ability of patients to access kidney transplant and home dialysis , which are essential steps toward improving patient centric kidney care.
  • "Kidney transplant is the gold standard treatment for kidney failure for most patients, providing better health outcomes, an improved quality of life, and cost savings when compared to dialysis.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org .

Essential Role of Ultrapure Dialysis Fluid Highlighted on World Patient Safety Day

Thursday, September 17, 2020 - 1:05am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200916005511/en/
    Fresenius Medical Care today announced the launch of the organizations first World Patient Safety Day initiative to raise awareness of the importance of ultrapure dialysis fluid for developing economies across Asia Pacific.
  • We have chosen World Patient Safety Day to highlight the importance of this issue.
  • These will begin with an online symposium presented on World Patient Safety Day, Does Ultrapure Dialysis Fluid Matter in Hemodialysis?
  • For more information about Ultrapure Dialysis Fluid, please visit: https://bit.ly/3moMk0Q
    The online symposium Does Ultrapure Dialysis Fluid Matter in Hemodialysis?

Dialysis Patient Citizens Commends Introduction of the BETTER Kidney Care Act

Wednesday, September 16, 2020 - 7:36pm

WASHINGTON, Sept. 16, 2020 /PRNewswire/ -- Dialysis Patient Citizens (DPC) today applauded introduction of theBETTER Kidney Care Act(H.R.

Key Points: 
  • WASHINGTON, Sept. 16, 2020 /PRNewswire/ -- Dialysis Patient Citizens (DPC) today applauded introduction of theBETTER Kidney Care Act(H.R.
  • "We applaud Senators Young and Sinema along with Representatives Blumenauer and Smith for introducing the BETTER Kidney Care Act.
  • "A study released in Health Affairs last week found a much higher survival rate for dialysis patients who participated in care coordination.
  • By establishing a system in which one entity takes responsibility for the overall care of their dialysis patient, theBETTER Kidney Care Actwould help to keep patients healthy, prevent unwanted complications, and reduce overall healthcare costs.

Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Tuesday, September 15, 2020 - 1:00pm

This is a special time for the Ardelyx team as we have a clear mission that we can and should do better for patients.

Key Points: 
  • This is a special time for the Ardelyx team as we have a clear mission that we can and should do better for patients.
  • We believe that with tenapanor, we have discovered and developed a therapy that will truly advance care for patients on dialysis."
  • The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of April 29, 2021.
  • Tenapanor, discovered and developed by Ardelyx, is a first-in-class, proprietary, oral medicine for which an NDA is under review by the FDA for the control of serum phosphorus in adult patients with CKD on dialysis.

Quanta to Host Expert Perspectives Webinar on Home Dialysis

Tuesday, September 15, 2020 - 12:00pm

Alcester, Warwickshire, UK, 15 September 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British medical technology innovation company, today announces that it will be hosting an Expert Perspectives Webinar on home dialysis on Monday 21 September at 4pm BST / 11am EDT.

Key Points: 
  • Alcester, Warwickshire, UK, 15 September 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British medical technology innovation company, today announces that it will be hosting an Expert Perspectives Webinar on home dialysis on Monday 21 September at 4pm BST / 11am EDT.
  • The presentation will be followed by a live moderated Q&A with the panel and audience by Tina Tan, Executive Editor at FirstWord MedTech.
  • The management team at Quanta Dialysis Technologies will also be available to discuss SC+, its small, simple and versatile haemodialysis system.
  • How quickly will dialysis be adopted routinely in North America?

Quanta to Host Expert Perspectives Webinar on Home Dialysis

Tuesday, September 15, 2020 - 8:00am

Alcester, Warwickshire, UK, 15 September 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British medical technology innovation company, today announces that it will be hosting an Expert Perspectives Webinar on home dialysis on Monday 21 September at 4pm BST / 11am EDT.

Key Points: 
  • Alcester, Warwickshire, UK, 15 September 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British medical technology innovation company, today announces that it will be hosting an Expert Perspectives Webinar on home dialysis on Monday 21 September at 4pm BST / 11am EDT.
  • The presentation will be followed by a live moderated Q&A with the panel and audience by Tina Tan, Executive Editor at FirstWord MedTech.
  • The management team at Quanta Dialysis Technologies will also be available to discuss SC+, its small, simple and versatile haemodialysis system.
  • How quickly will dialysis be adopted routinely in North America?

Peritoneal Dialysis Market Size to Reach Revenues of $4.5 Billion by 2025 - Arizton

Monday, September 14, 2020 - 5:00pm

The global peritoneal dialysis (PD) market sizeis expected to grow at a CAGR of over 6% during the period 20192025.

Key Points: 
  • The global peritoneal dialysis (PD) market sizeis expected to grow at a CAGR of over 6% during the period 20192025.
  • High usage and need for PD solution by patients is the key factors anticipated to drive the growth of the market.
  • The rising COVID-19 cases has increased the adoption of home-based peritoneal dialysis adoption as well as rising CKF prevalence is boosting PD adoption and fueling the market growth.
  • This has increased the PD adoption in the patient population and is boosting the market demand for PD products.

Microdialysis Market: COVID-19 Business Continuity Plan | Evolving Opportunities With Amuza Inc. and Bioanalytical Systems Inc. | Technavio

Monday, September 14, 2020 - 2:00pm

In addition, the increasing adoption of microdialysis in human clinical trials is anticipated to boost the growth of the microdialysis market.

Key Points: 
  • In addition, the increasing adoption of microdialysis in human clinical trials is anticipated to boost the growth of the microdialysis market.
  • The company offers a wide range of microdialysis probes, fraction collectors, pumps, rotating cage stages, large molecule microdialysis, AtmosLM, tubing, and instruments.
  • Bioanalytical Systems Inc. operates its business through segments such as Contract Research Services and Research Products.
  • The company offers a wide range of microdialysis probes, pumps, rotating cage stages, guiding cannulas, extended stylets, caging, and microdialysis systems.

Ellipsys System Offers Greater Patient Eligibility and Reduced Time to Dialysis

Thursday, September 10, 2020 - 1:10pm

The Ellipsys System had a technical success rate of 100 percent, and only 27.7 percent of patients required secondary interventions following fistula creation.

Key Points: 
  • The Ellipsys System had a technical success rate of 100 percent, and only 27.7 percent of patients required secondary interventions following fistula creation.
  • Overall, 79.5 percent of Ellipsys patients and 58 percent of WavelinQ patients were able to successfully begin dialysis with their fistula.
  • "For every patient, my goal is to create the best possible dialysis access with the fewest possible interventions," said Dr. Shahverdyan.
  • The company's Ellipsys Vascular Access System is an innovative, ultrasound-guided, single-catheter endoAVF system used to percutaneously create an arteriovenous fistula for hemodialysis access.